RANI
NASDAQ · Pharmaceuticals
Rani Therapeutics Holdings-A
$1.06
-0.08 (-7.02%)
Financial Highlights (FY 2026)
Revenue
4.46M
Net Income
-130,375,190
Gross Margin
—
Profit Margin
-2,920.0%
Rev Growth
+30.7%
D/E Ratio
12.36
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 42.7% | 42.7% |
| Operating Margin | -5,186.2% | -4,667.6% | 20.3% | 21.7% |
| Profit Margin | -2,920.0% | -2,774.0% | 16.4% | 15.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.46M | 3.41M | 51.04M | 44.44M |
| Gross Profit | — | — | 21.81M | 18.99M |
| Operating Income | -231,540,771 | -159,390,159 | 10.38M | 9.66M |
| Net Income | -130,375,190 | -89,748,868 | 8.38M | 6.94M |
| Gross Margin | — | — | 42.7% | 42.7% |
| Operating Margin | -5,186.2% | -4,667.6% | 20.3% | 21.7% |
| Profit Margin | -2,920.0% | -2,774.0% | 16.4% | 15.6% |
| Rev Growth | +30.7% | +30.7% | +13.5% | +18.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 64.64M | 64.64M | 49.86M | 51.71M |
| Total Equity | 5.23M | 5.23M | 50.59M | 54.70M |
| D/E Ratio | 12.36 | 12.36 | 0.99 | 0.95 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -227,074,451 | -164,999,792 | 12.88M | 11.35M |
| Free Cash Flow | — | — | 6.14M | 6.76M |